7-(哌嗪-1-基)-1H-吲哚 | 84807-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 7-(哌嗪-1-基)-1H-吲哚
• 中文别名: 7-(1-哌嗪基)-1H-呋喃
• 英文名称: 7-piperazin-1-yl-1H-indole
• 英文别名: 1-(7-indolyl)piperazine；7-(1-piperazinyl)indole；1H-Indole, 7-(1-piperazinyl)-
• CAS: 84807-10-3
• 化学式: C₁₂H₁₅N₃
• mdl: MFCD01754106
• 分子量: 201.271
• InChiKey: XKDAUEWDPSMDGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  31.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-(哌嗪-1-基)-1H-吲哚 在 氢气 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 生成 (3R)-N-[(2R)-3-(4-chlorophenyl)-1-[4-(1H-indol-7-yl)piperazin-1-yl]-1-oxopropan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035
• 作为产物：
  描述：

  7-(4-tert-butoxycarbonyl-piperazin-1-yl)-indole-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 生成 7-(哌嗪-1-基)-1H-吲哚
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035

文献信息

• Novel N-acylated heterocycles
  申请人：Recordati S.A.

  公开号：US20030162777A1

  公开（公告）日：2003-08-28

  Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.

  描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物，以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环，或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合，在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
• [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
  申请人：Clark D. Jerry

  公开号：US20050043309A1

  公开（公告）日：2005-02-24

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  这项发明涉及公式1的化合物 其中G、D、A、Z、Q、X、Y、R 1 和R 4 至R 7 的定义如规范中所述，制备这些化合物的方法以及用于制备这些化合物的中间体，以及含有这些化合物的药物组合物及其在治疗中枢神经系统疾病和其他疾病中的用途。
• Piperazine derivatives
  申请人：John Wyeth & Brother, Ltd.

  公开号：US05627177A1

  公开（公告）日：1997-05-06

  Piperazine derivatives of formula (I) and their pharmaceutically acceptable salts are 5-HT.sub.1A binding agents and may be used, for example, as anxiolytics. In the formula, A is an optionally substituted alkylene chain, Z is a specified bicyclic nitrogen containing heteroaromatic radical, R is hydrogen or lower alkyl, R.sup.1 is aryl or aryl(lower)alkyl and R.sup.2 and R.sup.3 are hydrogen or specified organic radicals or --NR.sup.2 R.sup.3 represents a heterocyclic ring. ##STR1##

  公式（I）的哌嗪衍生物及其药学上可接受的盐是5-HT.sub.1A结合剂，例如可用作抗焦虑药。在该公式中，A是可选择地取代的烷基链，Z是指定的含氮杂环芳基，R是氢或较低的烷基，R.sup.1是芳基或芳基(较低)烷基，R.sup.2和R.sup.3是氢或指定的有机基团，或--NR.sup.2 R.sup.3代表一个杂环环。
• N4-Unsubstituted N1-Arylpiperazines as High-Affinity 5-HT1A Receptor Ligands
  作者：Wilma Kuipers、Ineke van Wijngaarden、Chris G. Kruse、Marian ter Horst van Amstel、Martin Th. M. Tulp、Adriaan P. IJzerman

  DOI：10.1021/jm00011a014

  日期：1995.5

  found 2-methoxy substitution to be favorable, while 4-methoxy substitution was detrimental for 5-HT1A affinity. Substitution with annelated rings at the 2,3-positions was highly favorable for all investigated compounds, with the exception of a pyrrole ring. All other substitutions, except fluoro, in this class of heterobicyclic phenylpiperazines decreased affinity in the order: ortho > para > meta.

  为了探索对高5-HT1A亲和力的结构要求，合成了一系列芳基取代的N1-苯基哌嗪并评估了其从大鼠额叶皮层特定结合位点置换[3H] -8-OH-DPAT的能力。匀浆。我们发现2-甲氧基取代是有利的，而4-甲氧基取代对5-HT1A亲和力是有害的。除吡咯环外，对于所有研究的化合物，在2，3-位上用退火环取代非常有利。此类杂双环苯基哌嗪类中的所有其他取代基（氟基除外）按以下顺序降低亲和力：邻位>对位>间位。邻位和对位失去亲和力可能是由于空间因素：取代基或者与受体引起空间位阻，或者阻止化合物采用适当的构象与5-HT1A受体结合。构象分析与结构亲和性关系（SAR）结合表明，我们的芳基哌嗪可能以几乎共面的构象结合在5-HT1A受体上。在我们的5-HT1A受体模型中观察到的化合物的相互作用似乎与SAR数据一致。芳基哌嗪部分的芳族部分分别与螺旋IV和VI中的芳族残基Trp161和Phe362具有pi-pi相互
• New indole derivatives with 5HT6 receptor affinity
  申请人：——

  公开号：US20030073700A1

  公开（公告）日：2003-04-17

  This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I: 1 wherein one of R 5 , R 6 or R 7 is a group of general Formula B, wherein W is a —CH— group or a nitrogen atom, and the other substituents are as defined herein; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  本发明涉及具有通常的5-HT6受体亲和力的化合物，其由公式I表示：其中R5、R6或R7中的一个是一般式B的基团，其中W是一个-CH-基团或一个氮原子，其他取代基如本文所定义；或其个别异构体，消旋或非消旋异构体混合物，或其药学上可接受的盐或溶剂。本发明还涉及含有这种化合物的制药组合物，它们作为治疗剂的使用方法，以及它们的制备方法。